Friday, May 13, 2011
SpringLeaf Therapeutics Inc., of Boston, raised $15 million in a Series B financing to develop its drug-device combination system for the subcutaneous delivery of biologics. New investor SR One led the round, with participation from existing investors Flybridge Capital Partners and North Bridge Venture Partners.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.